Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:EDSA NASDAQ:IMMX NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.73+14.5%$4.16$2.14▼$7.55$513.29M1.51.34 million shs5.85 million shsEDSAEdesa Biotech$14.61-4.1%$8.35$0.72▼$20.32$135.42M1.261.09 million shs130,883 shsIMMXImmix Biopharma$10.10-3.7%$9.53$1.87▼$11.61$570.78M0.12740,067 shs759,909 shsVALNValneva$5.94+1.2%$7.19$5.06▼$12.25$505.45M1.7289,911 shs47,722 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-0.72%-2.36%-1.43%+10.13%+80.35%EDSAEdesa Biotech+14.85%+1.67%+158.31%+1,431.66%+662.00%IMMXImmix Biopharma-1.59%+1.65%+8.26%+41.18%+429.80%VALNValneva-2.17%+8.50%-4.24%-41.42%-7.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.73+14.5%$4.16$2.14▼$7.55$513.29M1.51.34 million shs5.85 million shsEDSAEdesa Biotech$14.61-4.1%$8.35$0.72▼$20.32$135.42M1.261.09 million shs130,883 shsIMMXImmix Biopharma$10.10-3.7%$9.53$1.87▼$11.61$570.78M0.12740,067 shs759,909 shsVALNValneva$5.94+1.2%$7.19$5.06▼$12.25$505.45M1.7289,911 shs47,722 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-0.72%-2.36%-1.43%+10.13%+80.35%EDSAEdesa Biotech+14.85%+1.67%+158.31%+1,431.66%+662.00%IMMXImmix Biopharma-1.59%+1.65%+8.26%+41.18%+429.80%VALNValneva-2.17%+8.50%-4.24%-41.42%-7.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.8086.05% UpsideEDSAEdesa Biotech 2.00Hold$5.00-65.78% DownsideIMMXImmix Biopharma 2.50Moderate Buy$18.2580.69% UpsideVALNValneva 2.20Hold$11.98101.60% UpsideCurrent Analyst Ratings BreakdownLatest EDSA, VALN, IMMX, and AQST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/22/2026VALNValneva The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$4.904/21/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026VALNValneva GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.003/30/2026IMMXImmix Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$14.00 ➝ $15.003/27/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026IMMXImmix Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$23.003/27/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $15.003/25/2026IMMXImmix Biopharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.003/9/2026IMMXImmix Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$23.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M13.20N/AN/A($0.28) per share-16.89EDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$1.55 per shareN/AVALNValneva$197.56M2.59N/AN/A$1.39 per share4.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.78N/AN/AN/A-137.08%N/A-49.49%N/AEDSAEdesa Biotech-$7.19M-$1.15N/AN/AN/AN/A-163.57%-52.54%N/AIMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%6/3/2026 (Estimated)VALNValneva-$130.33M-$1.58N/A3.26N/A-88.87%-95.00%-31.90%N/ALatest EDSA, VALN, IMMX, and AQST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49N/AN/A5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/13/2026Q1 2026VALNValneva-$0.21-$0.42-$0.21-$0.42$47.15 million$36.16 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A3/31/2026Q4 2025VALNValnevaN/A-$0.42N/A-$0.42N/A$35.77 million3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/4/2026Q4 2025AQSTAquestive Therapeutics-$0.13-$0.26-$0.13-$0.26$13.28 million$13.02 million2/15/2026Q4 2025 TUVALNValnevaN/A-$0.68N/A-$0.68N/A$55.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.143.01EDSAEdesa BiotechN/A16.8216.82IMMXImmix BiopharmaN/A8.7510.01VALNValneva1.522.381.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%EDSAEdesa Biotech5.50%IMMXImmix Biopharma11.26%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%EDSAEdesa Biotech24.40%IMMXImmix Biopharma30.30%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160124.29 million115.82 millionOptionableEDSAEdesa Biotech208.89 million6.72 millionNot OptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableVALNValneva70086.11 million73.27 millionNot OptionableEDSA, VALN, IMMX, and AQST HeadlinesRecent News About These CompaniesValneva SE (VALN) Q1 2026 Earnings Call TranscriptMay 13 at 11:39 PM | seekingalpha.comValneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...May 13 at 11:39 PM | uk.finance.yahoo.comValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccinesMay 13 at 11:39 PM | fiercebiotech.comFValneva Q1 Earnings Call HighlightsMay 13 at 3:09 PM | marketbeat.comValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13 at 1:00 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNMay 7, 2026 | prnewswire.comValneva (NASDAQ:VALN) vs. PURE Bioscience (OTCMKTS:PURE) Critical SurveyMay 7, 2026 | americanbankingnews.comVALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026May 5, 2026 | globenewswire.comValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026May 5, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 30, 2026 | prnewswire.comValneva Announces the Successful Completion of an €84 million Reserved OfferingApril 30, 2026 | globenewswire.comValneva (VALN) Expected to Announce Earnings on WednesdayApril 29, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 28, 2026 | globenewswire.comAs tick season drags longer, Pfizer hopes to release a Lyme disease vaccine in 2027April 27, 2026 | politifact.comPValneva (NASDAQ:VALN) Downgraded by Wall Street Zen to Strong SellApril 25, 2026 | marketbeat.comValneva's Commercial Crossroads: A Vaccine Maker's Pivotal YearApril 23, 2026 | aktiencheck.deAValneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst DowngradeApril 22, 2026 | marketbeat.comValneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by AnalystsApril 22, 2026 | marketbeat.comValneva (NASDAQ:VALN) Cut to "Sell" at The Goldman Sachs GroupApril 22, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNApril 21, 2026 | globenewswire.comA vaccine for Lyme disease could be on the horizonApril 20, 2026 | sciencenews.orgSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDSA, VALN, IMMX, and AQST Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.73 +0.60 (+14.53%) Closing price 04:00 PM EasternExtended Trading$4.72 -0.01 (-0.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Edesa Biotech NASDAQ:EDSA$14.61 -0.63 (-4.13%) Closing price 04:00 PM EasternExtended Trading$14.68 +0.07 (+0.44%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Immix Biopharma NASDAQ:IMMX$10.10 -0.39 (-3.72%) Closing price 04:00 PM EasternExtended Trading$10.10 0.00 (0.00%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Valneva NASDAQ:VALN$5.94 +0.07 (+1.19%) Closing price 04:00 PM EasternExtended Trading$5.95 +0.01 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
